The medical research community has announced a new clinical trial to investigate the effectiveness of Bactorinol® Nasal Spray in managing vasomotor rhinitis symptoms in adults. Sponsored by Liaquat University of Medical & Health Sciences in collaboration with the University of Urbino “Carlo Bo,” this study is expected to provide valuable data for healthcare professionals and regulatory stakeholders. Recruitment has not yet begun as of December 8, 2025.
In this article:
- What changed?
- What is the purpose of the study?
- Who will participate?
- What methodology will be used?
- Frequently Asked Questions
- What does this mean for clinicians?
- Disclaimer
- Link to trial details
What changed?
This clinical trial represents a focused effort to evaluate Bactorinol® Nasal Spray as a treatment device for adult patients suffering from vasomotor rhinitis. The spray will be assessed against isotonic saline solution, a common intervention in similar conditions. The trial’s start marks a significant milestone for both the sponsor institutions and the field of otolaryngology.
What is the purpose of the study?
The study aims to determine the performance and safety profile of Bactorinol® Nasal Spray in alleviating symptoms of vasomotor rhinitis. Vasomotor rhinitis is a non-allergic condition characterized by chronic nasal congestion, sneezing, and irritation. If proven effective, Bactorinol® could establish itself as a reliable therapeutic option.
Who will participate?
This trial will involve adult patients diagnosed with vasomotor rhinitis. Inclusion and exclusion criteria have not been detailed in the initial announcement, but such criteria typically aim to ensure clinical comparability and safety for all enrolled subjects.
Significance of participant selection
By targeting patients with confirmed vasomotor rhinitis, the study ensures that measured outcomes directly assess the efficacy of the intervention on the intended condition.
What methodology will be used?
Participants will be randomized into one of two groups to receive either Bactorinol® Nasal Spray or isotonic saline solution. Both products will be compared for their ability to reduce nasal symptoms, improve quality of life, and demonstrate safety across the trial period.
Performance endpoints
Key performance endpoints are expected to include symptom relief, minimized adverse effects, and long-term usability of the nasal spray device.
Frequently Asked Questions
- Q: Has recruitment started for the trial?
A: No, recruitment has not yet begun as of December 8, 2025. - Q: What are the interventions being studied?
A: Bactorinol® Nasal Spray and isotonic saline solution. - Q: Who is sponsoring this trial?
A: Liaquat University of Medical & Health Sciences and the University of Urbino “Carlo Bo.” - Q: Where can I find more details about the trial?
A: Details can be accessed through the official ClinicalTrials.gov record linked at the end of this article.
What does this mean for clinicians?
The trial could yield important insights into effective management strategies for vasomotor rhinitis. Results could guide clinical decision-making and influence product approvals under medical device regulations.
Disclaimer
This article is for informational purposes only. It does not constitute legal or clinical advice. Users should consult official trial documents for detailed guidance.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07266688?term=medical+device